Cytosorbents (NASDAQ: CTSO) reported Q4 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $10.57 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.